A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Eli Lilly and Company
Study ID
NCT02734160
Phase
PHASE1
Status
Completed

Conditions

  • Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Galunisertib — DRUG
    Administered orally
  • Durvalumab — DRUG
    Administered IV

Study Details

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody durvalumab in participants with refractory metastatic pancreatic cancer.

Key Dates

Start date
Jun 15, 2016
Status verified
Aug 2019
Primary completion
Aug 2, 2018
Completion
Apr 17, 2019

Study Design

Enrollment
37 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Galunisertib + Durvalumab
    (Dose Escalation and Cohort Expansion) Galunisertib administered orally in combination with durvalumab administered intravenously (IV).

Primary Outcome Measure

Number of Participants with Galunisertib in Combination with Durvalumab Dose-Limiting Toxicities (DLTs) [ Time Frame: Cycle 1 (28 Days) ]

Locations (4)

FacilityCityStateZIPSite coordinators
Honor Health Research InstituteScottsdaleArizona85258-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Sarah Cannon Research Institute SCRINashvilleTennessee37203-
Tennessee Oncology PLLCNashvilleTennessee37203-

Find similar trials in Scottsdale, AZ

By research site
Honor Health Research Institute· Scottsdale, AZMemorial Sloan Kettering Cancer Center· New York, NYSarah Cannon Research Institute SCRI· Nashville, TNTennessee Oncology PLLC· Nashville, TN

Related Studies